In addition, the insights gained from the complex structure of mogamulizumab and its epitope peptide may offer critical information for designing a novel cancer vaccine that elicits an immune response against CCR4 for the treatment of CTCL. Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.